Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Ten Tije AJ, Verweij J, Sparreboom A, Van Der Gaast A, Fowst C, Fiorentini F, Tursi J, Antonellini A, Mantel M, Hartman CM, Stoter G, Planting AS, De Jonge MJ. Ten Tije AJ, et al. Among authors: fowst c. Clin Cancer Res. 2003 Aug 1;9(8):2957-64. Clin Cancer Res. 2003. PMID: 12912942 Clinical Trial.
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, Fowst C, de Balincourt C, di Paola ED, van Glabbeke M, Judson I, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Leahy M, et al. Among authors: fowst c. Eur J Cancer. 2007 Jan;43(2):308-15. doi: 10.1016/j.ejca.2006.09.014. Epub 2006 Nov 13. Eur J Cancer. 2007. PMID: 17095209 Clinical Trial.
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML. Lockhart AC, et al. Among authors: fowst c. Clin Cancer Res. 2004 Jan 15;10(2):468-75. doi: 10.1158/1078-0432.ccr-0658-03. Clin Cancer Res. 2004. PMID: 14760067 Clinical Trial.
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC. Postel-Vinay S, et al. Among authors: fowst c. Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28. Eur J Cancer. 2014. PMID: 24880774
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.
Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G. Lønning PE, et al. Among authors: fowst c. J Clin Oncol. 2000 Jun;18(11):2234-44. doi: 10.1200/JCO.2000.18.11.2234. J Clin Oncol. 2000. PMID: 10829043 Clinical Trial.
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P, Xu H, Jakubczak JL, English PA, Pierce KJ, Burris HA. Schöffski P, et al. Among authors: fowst c. Eur J Cancer. 2011 Oct;47(15):2256-64. doi: 10.1016/j.ejca.2011.07.008. Epub 2011 Aug 16. Eur J Cancer. 2011. PMID: 21852114 Clinical Trial.
28 results